Emricasan Disappoints for Severe Portal HTN in NASH

(MedPage Today) -- Week 24 analysis of 48-week trial did not meet primary endpoint

Source link

Related posts

Fatty liver, cirrhosis double mortality risk in COVID-19


Gastric Parietal Cell Physiology And Helicobacter Pylori-Induced Disease


Use of 'High-Risk' Antibiotic Classes in Hospitals Tied to More C. Difficile Infections


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy